Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers

Hepato-Gastroenterology

Volumn 59, Issue 118, 2012, Pages 1844-1850

  Deguchi, Tomohiro ^a   Shikano, Toshio ^a   Kasuya, Hideki ^a   Nawa, Akihiro ^a   Fujiwara, Sawako ^a   Takeda, Shin ^a   Gewen, Tan ^a   Sahin, Tevfik T ^a   Yamada, Suguru ^a   Kanzaki, Akiyuki ^a   Yamamura, Kazuo ^a   Fujii, Tsutomu ^a   Sugimoto, Hiroyuki ^a   Nomoto, Shuji ^a   Fukuda, Saori ^a   Nishikawa, Yoko ^a   Kodera, Yasuhiro ^a   Nakao, Akimasa ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CENTRAL HOSPITAL   (Japan)

Author keywords

Bevacizumab; Gastric cancer; Herpes virus; Oncolytic virus; Vastin

Indexed keywords

BETA GALACTOSIDASE; BEVACIZUMAB; CD31 ANTIGEN; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; VERO CELL; VIRUS CYTOTOXICITY; VIRUS REPLICATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHEMOTHERAPY, ADJUVANT; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HERPESVIRUS 1, HUMAN; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; STOMACH NEOPLASMS; TIME FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867719746     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11566     Document Type: Article

References (35)

1. Liu H, Liu S, Wu Y, et al.: Cloning and expression of a single human immunoglobulin heavy-chain variable domain with vascular endothelial growth factor binding activity. Sheng Wu Gong Cheng Xue Bao 2010; 26(11):1555-1562.
2. Teoh DG, Secord AA: Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011; 18(1):31-43.
3. Yamamoto H, Yamada T, Takabayashi T, et al.: Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase Enhanced Human IgE Production. Allergol Int 2011; 60(1):79-85.
4. El-Rayes B. F, Zalupski M, Bekai-Saab T, et al.: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010; 21(10):1999-2004.
5. Yagi Y, Fushida S, Harada S, et al.: Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol 2010; 66(4):745-753.
6. Aghi M, Rabkin SD, Martuza RL: Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007; 67(2):440-444. (Pubitemid 46192178)
7. Shikano T, Kasuya H, Sahin TT, et al.: High Therapeutic Potential for Systemic Delivery of a Liposome-conjugated Herpes Simplex Virus. Curr Cancer Drug Targets 2010; 11(1):111-122.
8. Kulu Y, Dorfman JD, Kuruppu D, et al.: Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 2009; 16(4):291-297.
9. Nomura N, Kasuya H, Watanabe I, et al.: Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Cancer Chemother Pharmacol 2009; 63(2):321-330.
10. Libertini S, Iacuzzo I, Perruolo G, et al.: Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus d1922-947. Clin Cancer Res 2008; 14(20):6505-6514.
11. Bilbao R, Bustos M, Alzuguren P, et al.: A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther 2000; 7(21):1824-1832.
12. McKee T. D, Grandi P, Mok W, et al.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66(5):2509-2513.
13. Ram Z, Culver K. W, Oshiro E. M, et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3(12):1354-1361. (Pubitemid 28011035)
14. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46(1-3):149-168.
15. Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer 2006; 6(8): 583-592. (Pubitemid 44140857)
16. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7(9):987-989.
17. Salnikov AV, Heldin NE, Stuhr LB, et al.: Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 2006; 119(12):2795-2802. (Pubitemid 44846230)
18. Eshun FK, Currier MA, Gillespie RA, et al.: VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther 2010; 17(7):922-929.
19. Wojton J, Kaur B: Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 2010; 21(2-3):127-134.
20. Tong RT, Boucher Y, Kozin SV, et al.: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64(11):3731-3736. (Pubitemid 38697278)
21. Boucher Y, Leunig M, Jain RK: Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56(18):4264-4266. (Pubitemid 26305026)
22. Boucher Y, Jain RK: Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992; 52(18):5110-5114.
23. Hashizume H, Baluk P, Morikawa S, et al.: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156(4):1363-1380. (Pubitemid 30660013)
24. Stohrer M, Boucher Y, Stangassinger M, et al.: Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60(15):4251-4255. (Pubitemid 30636613)
25. Smirne C, Camandona M, Rosso E, et al.: Emanuelli, G. Vascular endothelial growth factor. From basic research to clinical application. Minerva Med 1999; 90(l-2):15-23. (Pubitemid 29263720)
26. Tromp SC, oude Egbrink MG, Dings RP, et al.: Tumor angiogenesis factors reduce leukocyte adhesion in vivo, Int Immunol 2000; 12(5):671-676.
27. Gabrilovich DI, Ishida T, Nadaf S, et al.: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5(10):2963-2970. (Pubitemid 29493976)
28. Bourla DH, Dotan A, Weinberger D, et al.: Consecutive appearance of corneal subepithelial infiltrates after intravitreous bevacizumab injections. Cornea 2010; 29(6):686-687.
29. Roland CL, Dineen SP, Lynn KD, et al.: Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009; 8(7):1761-1771.
30. Laschos KA, Papazisis KT, Kontovinis LF, et al.: Targeted treatment for metastatic renal cell carcinoma and immune regulation. J BUON 2010; 15(2):235-240.
31. Bellati F, Napoletano C, Ruscito I, et al.: Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 2010; 28(6):887-894.
32. Todo T: Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008; 13:2060-2064.
33. Shimoyama S, Goshima F, Teshigahara O, et al.: Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology 2007; 54(76):1038-1042. (Pubitemid 47013900)
34. Mantovani A, Romero P, Palucka AK, et al.: Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371(9614):771-783.
35. Yao F, Murakami N, Bleiziffer O, et al.: Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. J Virol 2010; 84(16):8163-8171.